8-K: Supernus Pharmaceuticals Reports Strong Q4 and Full Year 2024 Financial Results; Qelbree Sales Surge

Supernus Pharmaceuticals announces positive financial results for Q4 and full year 2024, driven by significant growth in Qelbree sales and overall operating earnings, while also providing 2025 revenue guidance.

Summary

• Supernus Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Full year 2024 revenues increased by 9% to $661.8 million compared to $607.5 million in 2023.
• Excluding Trokendi XR and Oxtellar XR, revenues increased by 25% for the full year 2024.
• Qelbree net sales increased by 60% in Q4 2024 to $74.4 million and 72% for the full year to $241.3 million.
• GOCOVRI net sales increased by 15% in Q4 2024 to $36.9 million and 9% for the full year to $130.8 million.
• Operating earnings for the full year 2024 were $81.7 million, a significant improvement from the operating loss of $(5.3) million in 2023.
• Adjusted operating earnings increased by 47% to $183.7 million for the full year 2024.
• The company is launching ONAPGO in the second quarter of 2025.
• Full year 2025 revenue guidance is projected to be between $600 million and $630 million.
• The company expects operating earnings (loss) of $(15) million to $10 million and adjusted operating earnings of $105 million to $130 million for 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to strong growth in key products and improved profitability. However, the negative results from the SPN-820 trial and projected lower operating earnings for 2025 temper the overall outlook.

Positives

• Significant growth in Qelbree and GOCOVRI sales indicates strong commercial execution.
• Substantial improvement in operating earnings and adjusted operating earnings reflects enhanced profitability.
• FDA approval and planned launch of ONAPGO provides a new revenue stream and expands the product portfolio.
• Patent extension for Qelbree provides long-term market exclusivity.
• The company's cash position increased to $453.6 million, providing financial flexibility.
• The updated Qelbree label includes new pharmacodynamic and lactation data, enhancing its market position.
• Phase IV trial data suggests Qelbree's effects may extend to adults with complex ADHD.

Negatives

• Decline in net product sales of Trokendi XR and Oxtellar XR due to generic erosion.
• SPN-820 Phase 2b study for treatment-resistant depression did not demonstrate statistically significant improvement on primary and secondary endpoints.
• Full year 2025 operating earnings are projected to be between $(15) million and $10 million, lower than 2024.
• Royalty, licensing and other revenues decreased 28% for the full year.

Risks

• Continued generic erosion of Trokendi XR and Oxtellar XR could impact future revenue.
• The failure of SPN-820 to meet endpoints in the Phase 2b study raises concerns about the pipeline.
• The company's ability to successfully launch and commercialize ONAPGO is subject to market acceptance and competition.
• The company's ability to sustain and increase its profitability is subject to various risks and uncertainties.
• The company's ability to raise sufficient capital to fully implement its corporate strategy is subject to various risks and uncertainties.
• The company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the company's product candidates is subject to various risks and uncertainties.

Future Outlook

The company anticipates continued growth for Qelbree, the launch of ONAPGO in Q2 2025, and further advancement of its product pipeline. Full year 2025 revenue is projected to be between $600 million and $630 million, with adjusted operating earnings between $105 million and $130 million.

Management Comments

• Our 2024 results reflect solid commercial execution across the company, including continued growth of our core products, and strong growth in operating earnings, said Jack Khattar, President and CEO of Supernus.
• In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson's disease, planned for the second quarter of 2025; and further advancement of our product pipeline.

Industry Context

Supernus's focus on CNS diseases aligns with the growing need for treatments in areas like ADHD, Parkinson's, and epilepsy. The approval and launch of ONAPGO positions the company in the competitive Parkinson's disease market, while the growth of Qelbree highlights its success in the ADHD space.

Comparison to Industry Standards

• Supernus's 72% growth in Qelbree sales significantly outpaces the average growth rate for ADHD medications, suggesting strong market penetration and acceptance.
• The company's adjusted operating earnings growth of 47% demonstrates efficient cost management and revenue generation compared to its peers.
• While companies like Teva and Mylan face generic erosion challenges, Supernus is actively diversifying its portfolio with new products like ONAPGO to mitigate these risks.
• Compared to companies like Neurocrine Biosciences and Acadia Pharmaceuticals, which also focus on CNS disorders, Supernus is demonstrating a balanced approach with both commercialized products and a robust pipeline.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and profitability.
• Employees may see increased job security and potential for growth.
• Patients will have access to new treatment options like ONAPGO.
• Suppliers may see increased demand for their products and services.
• Creditors will have increased confidence in the company's ability to repay debts.

Next Steps

• Launch ONAPGO in the second quarter of 2025.
• Present topline results from the full Phase IV trial of Qelbree at the American Psychiatric Association Annual Meeting in May 2025.
• Continue analyzing data from the SPN-820 Phase 2b study to determine the future of the program.
• Continue the Phase 2b study of SPN-817 in patients with treatment-resistant focal seizures.

Key Dates